{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:33:56Z","timestamp":1768700036533,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-023-09641-w","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T05:02:26Z","timestamp":1681534946000},"page":"7274-7283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic value of TLR from FDG PET\/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"Hye Lim","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ha","family":"Boo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya Youngju","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Whan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ie Ryung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"9641_CR1","doi-asserted-by":"crossref","unstructured":"Postmus PE, Kerr KM, Oudkerk M et al (2017) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv1-iv21","DOI":"10.1093\/annonc\/mdx222"},{"key":"9641_CR2","unstructured":"National Comprehensive Cancer Network Non-Small Cell Lung Cancer (Version3.2022). Available via https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 3 June 2022"},{"key":"9641_CR3","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1245\/s10434-020-09362-0","volume":"28","author":"Z Zuo","year":"2021","unstructured":"Zuo Z, Zhang G, Song P et al (2021) Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol 28:3941\u20133950","journal-title":"Ann Surg Oncol"},{"key":"9641_CR4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jtcvs.2018.02.108","volume":"156","author":"L Okiror","year":"2018","unstructured":"Okiror L, Harling L, Toufektzian L et al (2018) Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer. J Thorac Cardiovasc Surg 156:785\u2013793","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9641_CR5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.athoracsur.2013.11.002","volume":"97","author":"NM Mollberg","year":"2014","unstructured":"Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK (2014) Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg 97:965\u2013971","journal-title":"Ann Thorac Surg"},{"key":"9641_CR6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.xjon.2022.03.002","volume":"10","author":"T Peng","year":"2022","unstructured":"Peng T, Wightman SC, Ding L et al (2022) Lobectomy offers improved survival outcomes relative to segmentectomy for >2 but \u22644 cm non-small cell lung cancer tumors. JTCVS Open 10:356\u2013367","journal-title":"JTCVS Open"},{"key":"9641_CR7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.athoracsur.2018.01.032","volume":"105","author":"J Cao","year":"2018","unstructured":"Cao J, Yuan P, Wang Y et al (2018) Survival rates after lobectomy, segmentectomy, and wedge resection for non-small cell lung cancer. Ann Thorac Surg 105:1483\u20131491","journal-title":"Ann Thorac Surg"},{"key":"9641_CR8","volume":"7","author":"X Hou","year":"2022","unstructured":"Hou X, Yang MZ, Li JB et al (2022) Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy? ESMO Open 7:100508","journal-title":"ESMO Open"},{"key":"9641_CR9","doi-asserted-by":"crossref","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT (2017) The eighth edition lung cancer stage classification. Chest 151:193\u2013203","DOI":"10.1016\/j.chest.2016.10.010"},{"key":"9641_CR10","unstructured":"Lung cancer survival rates. Available via https:\/\/www.cancer.org\/cancer\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed 30 June 2022"},{"key":"9641_CR11","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","volume":"26","author":"GM Strauss","year":"2008","unstructured":"Strauss GM, Herndon JE 2nd, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043\u20135051","journal-title":"J Clin Oncol"},{"key":"9641_CR12","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.cllc.2016.06.009","volume":"18","author":"KM Wong","year":"2017","unstructured":"Wong KM, Ding K, Li S et al (2017) A cost-effectiveness analysis of using the JBR.10-based 15-gene expression signature to guide adjuvant chemotherapy in early stage non-small-cell lung cancer. Clin Lung Cancer 18:e41\u2013e47","journal-title":"Clin Lung Cancer"},{"key":"9641_CR13","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1200\/JCO.2006.09.4342","volume":"25","author":"R Ng","year":"2007","unstructured":"Ng R, Hasan B, Mittmann N et al (2007) Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer\u2013a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:2256\u20132261","journal-title":"J Clin Oncol"},{"key":"9641_CR14","volume":"11","author":"J Liu","year":"2016","unstructured":"Liu J, Dong M, Sun X, Li W, Xing L, Yu J (2016) Prognostic value of 18F-FDG PET\/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One 11:e0146195","journal-title":"PLoS One"},{"key":"9641_CR15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/MNM.0000000000000382","volume":"36","author":"EJ Han","year":"2015","unstructured":"Han EJ, Yang YJ, Park JC, Park SY, Choi WH, Kim SH (2015) Prognostic value of early response assessment using 18F-FDG PET\/CT in chemotherapy-treated patients with non-small-cell lung cancer. Nucl Med Commun 36:1187\u20131194","journal-title":"Nucl Med Commun"},{"key":"9641_CR16","first-page":"3091","volume":"24","author":"R YooIe","year":"2014","unstructured":"YooIe R, Chung SK, Park HL et al (2014) Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET\/CT in early stage non-small cell lung cancer patients without LN metastasis. Biomed Mater Eng 24:3091\u20133103","journal-title":"Biomed Mater Eng"},{"key":"9641_CR17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"9641_CR18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"O Jh","year":"2016","unstructured":"Jh O, Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 280:576\u2013584","journal-title":"Radiology"},{"key":"9641_CR19","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s00259-017-3779-0","volume":"44","author":"J Huang","year":"2017","unstructured":"Huang J, Huang L, Zhou J et al (2017) Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET\/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging 44:1958\u20131968","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9641_CR20","volume":"14","author":"MN Toledano","year":"2019","unstructured":"Toledano MN, Vera P, Tilly H, Jardin F, Becker S (2019) Comparison of therapeutic evaluation criteria in FDG-PET\/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor\/liver ratio. PLoS One 14:e0211649","journal-title":"PLoS One"},{"key":"9641_CR21","volume":"131","author":"C Wu","year":"2020","unstructured":"Wu C, Cui Y, Zhao Y et al (2020) Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative (18)F-FDG PET\/CT predicts poor prognosis of patients with clear cell renal cell carcinoma after nephrectomy. Eur J Radiol 131:109218","journal-title":"Eur J Radiol"},{"key":"9641_CR22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00432-019-02858-7","volume":"145","author":"HL Park","year":"2019","unstructured":"Park HL, Yoo IR, Boo SH et al (2019) Does FDG PET\/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients? J Cancer Res Clin Oncol 145:1021\u20131026","journal-title":"J Cancer Res Clin Oncol"},{"key":"9641_CR23","doi-asserted-by":"crossref","unstructured":"Wu LL, Liu X, Jiang WM et al (2020) Stratification of patients with stage IB NSCLC based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual. Front Oncol 10:571","DOI":"10.3389\/fonc.2020.00571"},{"key":"9641_CR24","doi-asserted-by":"crossref","unstructured":"Consonni D, Pierobon M, Gail MH et al (2015) Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Inst 107:djv059","DOI":"10.1093\/jnci\/djv059"},{"key":"9641_CR25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/1759-7714.13685","volume":"12","author":"P Zhang","year":"2021","unstructured":"Zhang P, Duan J, Bai H et al (2021) Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer. Thorac Cancer 12:30\u201339","journal-title":"Thorac Cancer"},{"key":"9641_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2019.04.024","volume":"133","author":"X Li","year":"2019","unstructured":"Li X, Zhang C, Sun Z et al (2019) Propensity-matched analysis of adjuvant chemotherapy for completely resected stage IB non-small-cell lung cancer patients. Lung Cancer 133:75\u201382","journal-title":"Lung Cancer"},{"key":"9641_CR27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00432-018-2801-7","volume":"145","author":"J Wang","year":"2019","unstructured":"Wang J, Wu N, Lv C, Yan S, Yang Y (2019) Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients. J Cancer Res Clin Oncol 145:463\u2013469","journal-title":"J Cancer Res Clin Oncol"},{"key":"9641_CR28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.JTO.0000268669.64625.bb","volume":"2","author":"L Horn","year":"2007","unstructured":"Horn L, Sandler AB, Putnam JB Jr, Johnson DH (2007) The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. J Thorac Oncol 2:377\u2013383","journal-title":"J Thorac Oncol"},{"key":"9641_CR29","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00432-020-03276-w","volume":"146","author":"J Xie","year":"2020","unstructured":"Xie J, Zhang X, Hu S et al (2020) Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion. J Cancer Res Clin Oncol 146:2231\u20132239","journal-title":"J Cancer Res Clin Oncol"},{"key":"9641_CR30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","volume":"7","author":"JY Douillard","year":"2006","unstructured":"Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719\u2013727","journal-title":"Lancet Oncol"},{"key":"9641_CR31","doi-asserted-by":"crossref","unstructured":"Amin MB, Greene FL, Edge SB et al (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin 67:93\u201399","DOI":"10.3322\/caac.21388"},{"key":"9641_CR32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13000-015-0249-5","volume":"10","author":"R Hamanaka","year":"2015","unstructured":"Hamanaka R, Yokose T, Sakuma Y et al (2015) Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer. Diagn Pathol 10:17","journal-title":"Diagn Pathol"},{"key":"9641_CR33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/SLA.0000000000000617","volume":"260","author":"S Neri","year":"2014","unstructured":"Neri S, Yoshida J, Ishii G et al (2014) Prognostic impact of microscopic vessel invasion and visceral pleural invasion in non-small cell lung cancer: a retrospective analysis of 2657 patients. Ann Surg 260:383\u2013388","journal-title":"Ann Surg"},{"key":"9641_CR34","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1245\/s10434-015-4411-9","volume":"22","author":"HC Yang","year":"2015","unstructured":"Yang HC, Kim HR, Jheon S et al (2015) Recurrence risk-scoring model for Stage I Adenocarcinoma of the Lung. Ann Surg Oncol 22:4089\u20134097","journal-title":"Ann Surg Oncol"},{"key":"9641_CR35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","volume":"399","author":"H Saji","year":"2022","unstructured":"Saji H, Okada M, Tsuboi M et al (2022) Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 399:1607\u20131617","journal-title":"Lancet"},{"key":"9641_CR36","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/MNM.0000000000000144","volume":"35","author":"M Su","year":"2014","unstructured":"Su M, Li Y, Li F, Li L, Tian R (2014) Risk factors for N2 metastasis in patients with non-small-cell lung cancer: multivariate analyses of 18F-FDG PET\/CT data. Nucl Med Commun 35:916\u2013921","journal-title":"Nucl Med Commun"},{"key":"9641_CR37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s13139-012-0165-5","volume":"46","author":"SW Yoo","year":"2012","unstructured":"Yoo SW, Kim J, Chong A et al (2012) Metabolic tumor volume measured by F-18 FDG PET\/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging 46:286\u2013293","journal-title":"Nucl Med Mol Imaging"},{"key":"9641_CR38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/1759-7714.13863","volume":"12","author":"X Qiu","year":"2021","unstructured":"Qiu X, Liang H, Zhong W et al (2021) Prognostic impact of maximum standardized uptake value on (18) F-FDG PET\/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: a retrospective study. Thorac Cancer 12:845\u2013853","journal-title":"Thorac Cancer"},{"key":"9641_CR39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2214\/AJR.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, Wong TZ (2010) A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195:310\u2013320","journal-title":"AJR Am J Roentgenol"},{"key":"9641_CR40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnmt.111.090027","volume":"39","author":"E Laffon","year":"2011","unstructured":"Laffon E, Adhoute X, de Clermont H, Marthan R (2011) Is liver SUV stable over time in 18F-FDG PET imaging? J Nucl Med Technol 39:258\u2013263","journal-title":"J Nucl Med Technol"},{"key":"9641_CR41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11307-008-0177-9","volume":"11","author":"BB Chin","year":"2009","unstructured":"Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE (2009) Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol 11:118\u2013122","journal-title":"Mol Imaging Biol"},{"key":"9641_CR42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-022-05977-5","volume":"50","author":"GJC Zwezerijnen","year":"2023","unstructured":"Zwezerijnen GJC, Eertink JJ, Ferr\u00e1ndez MC et al (2023) Reproducibility of [18F]FDG PET\/CT liver SUV as reference or normalisation factor. Eur J Nucl Med Mol Imaging 50:486\u2013493","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9641_CR43","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00259-019-04327-2","volume":"46","author":"CH Lim","year":"2019","unstructured":"Lim CH, Moon SH, Cho YS, Choi JY, Lee KH, Hyun SH (2019) Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with combined hepatocellular-cholangiocarcinoma. Eur J Nucl Med Mol Imaging 46:1705\u20131712","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9641_CR44","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3389\/fonc.2020.01630","volume":"10","author":"C Wang","year":"2020","unstructured":"Wang C, Zhao K, Hu S et al (2020) The PET-derived tumor-to-liver standard uptake ratio (SUV (TLR) ) is superior to tumor SUVmax in predicting tumor response and survival after chemoradiotherapy in patients with locally advanced esophageal cancer. Front Oncol 10:1630","journal-title":"Front Oncol"},{"key":"9641_CR45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2967\/jnumed.115.167338","volume":"57","author":"JW Lee","year":"2016","unstructured":"Lee JW, Oh JK, Chung YA et al (2016) Prognostic significance of 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: a Multicenter retrospective cohort study. J Nucl Med 57:509\u2013516","journal-title":"J Nucl Med"},{"key":"9641_CR46","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s00259-014-2774-y","volume":"41","author":"A Piccardo","year":"2014","unstructured":"Piccardo A, Puntoni M, Bertagna F et al (2014) 18F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET\/CT: a multicentre study. Eur J Nucl Med Mol Imaging 41:1482\u20131491","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9641_CR47","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s00259-018-4016-1","volume":"45","author":"L Evangelista","year":"2018","unstructured":"Evangelista L, Cuocolo A, Pace L et al (2018) Performance of FDG-PET\/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. Eur J Nucl Med Mol Imaging 45:1898\u20131907","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9641_CR48","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","volume":"11","author":"JJ Lin","year":"2016","unstructured":"Lin JJ, Cardarella S, Lydon CA et al (2016) Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 11:556\u2013565","journal-title":"J Thorac Oncol"},{"key":"9641_CR49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2021.09.003","volume":"162","author":"C Aggarwal","year":"2021","unstructured":"Aggarwal C, Bubendorf L, Cooper WA et al (2021) Molecular testing in stage I-III non-small cell lung cancer: approaches and challenges. Lung Cancer 162:42\u201353","journal-title":"Lung Cancer"},{"key":"9641_CR50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","volume":"112","author":"R Brody","year":"2017","unstructured":"Brody R, Zhang Y, Ballas M et al (2017) PD-L1 expression in advanced NSCLC:insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112:200\u2013215","journal-title":"Lung Cancer"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09641-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-023-09641-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09641-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:03:18Z","timestamp":1695211398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-023-09641-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["9641"],"URL":"https:\/\/doi.org\/10.1007\/s00330-023-09641-w","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Ie Ryung Yoo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Department of Biostatistics at the Catholic University kindly provided statistical advice for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}